LAMP1 and neoplasm: We exposed the TIL products for 6–7 h to autologous tumor digest, and we measured the expression of the activation marker CD137 (4-1BB) indicative of TCR triggering (Ye et al, 2014), the degranulation marker CD107a, and TNF and IFNγ required for effective antitumoral responses (Patel et al, 2017) (Fig 3A).